期刊文献+

“异病同治”与肿瘤基于基因的个体化治疗 被引量:2

Same Treatment for Different Diseases and Individualized Treatment for Tumor Based on Gene
原文传递
导出
摘要 辨证论治指导下的中医治疗存在"异病同治"的现象,西医在肿瘤治疗中存在不同肿瘤因为具有相同的基因分型,而选择相同的治疗方案,也存在着"异病同治"的情况。中医"异病同治"的"证"与不同肿瘤个体化治疗的基因存在着共性,我们可以认为"证"与基因改变之间可能会存在着一定内在的、本质联系,基因状况应是中医"异病同治""证"研究的核心,"异病同治"可以作为中西医结合的一个桥梁而深入研究。 The phenomena of same treatments for different diseases in traditional Chinese medicine is guided by treatment based on syndrome differentiation.Since different tumors may have similar genetic basis and then have the same treatments,the phenomena also exists in the Western medicine treatment specialized in oncology.The differentiations in traditional Chinese medicine have commons with genes from patients with tumors in personalized therapy.Therefore,we conclude that differentiations harbor certain intrinsic,essential relationships with the gene circumstances.The gene status should be the core of the research on differentiation in the same treatments for different diseases of traditional Chinese medicine,which can be taken as a bridge to integrate the traditional Chinese medicine and Western medicine research.
出处 《辽宁中医药大学学报》 CAS 2012年第5期51-52,共2页 Journal of Liaoning University of Traditional Chinese Medicine
基金 江苏省高校优势学科建设工程资助项目 江苏省中医药领军人才资助项目(LJ200908)
关键词 异病同治 肿瘤基因 个体化治疗 same treatments for different diseases gene in tumors personalized therapy
  • 相关文献

参考文献2

二级参考文献6

  • 1Druker BJ, Talpaz M,Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia[J]. N Engl J Med ,2001,344(14): 1031 - 1037.
  • 2Kantarjian H, Sawyers C, Hochhaus A, et al. Phase Ⅱ study of STI571, a tyrosine kinase inhibitor in patients with resistant or refractory Philadelphia chromosome positive chronic myedloid leukemia[ J ]. Blood, 2000,96: 470a.
  • 3Hughes TP, Kaeda J, Branford S, et al. International Randomised Study of Interferon versus STI571 (IRIS) Study Group. Requency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia [ J ]. N Engl J Med ,2003,349(15): 1423 - 32.
  • 4Demetri GD,Mehren M,Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors[J]. N Engl J Med, 2002,347(7) :472 - 480.
  • 5Weisberg E,Griffin JD. Mechanism of resistance to the ABL tyro sine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines[ J ]. Blood, 2000,1,95 ( 11 ): 3498 - 505.
  • 6Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification[ J ]. Science, 2001,293 (5531): 876 - 880.

共引文献19

同被引文献58

引证文献2

二级引证文献39

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部